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Since its introduction more than 3 decades ago, the use of peritoneal dialysis (PD) has increased greatly due to its simplicity,
convenience, and low cost. Advances in technique, antibiotic prophylaxis, and the introduction of newer solutions have improved
survival, quality of life, and reduced rate of complications with PD. In Hong Kong, approximately 80% end-stage renal disease
(ESRD) patients perform PD; in others, that is, Canada, Australia, and New Zealand, 20%–30% patients use PD. However, in the
United States, the annual rate of prevalent patients receiving PD has reduced to 8% from its peak of 15% in mid-1980s. PD as
the initial modality is being oﬀered to far less patients than hemodialysis (HD), resulting in the current annual incidence rate
of less than 10% in USA. There are many reasons preventing the PD ﬁrst initiative including the increased numbers of in-center
hemodialysis units, physician comfort with the modality, perceived superiority of HD, risk of peritonitis, achieving adequate
clearances,and reimbursement incentives to providers. Patient fatigue, membranefailure, andcatheter problems are otherreasons
which discourage PD utilization.In this paper, we discuss the available evidence and provide rationale to support PD as the initial
renal replacement modality for ESRD patients.
1.Introduction
Over half million Americans were undergoing renal replace-
ment therapy (RRT) for ESRD at the end of year 2008.
In-center Hemodialysis (HD) and home PD are the two
common forms for dialysis therapy. Only about 8% of
patients with ESRD are receiving PD as RRT in the United
States compared to Canada and Europe, where PD is
much more common [1]. The percentage PD patients has
declined signiﬁcantly from the peak of 15% in the mid-
eighties to 5.8% in 2007 [1]. There are numerous factors
contributing to the low incidence and prevalence of PD
in this country [2, 3]. Concerns regarding achievement of
adequate clearance with PD, especially in patient with no
residual renal function and a perception of better patient
survival on HD compared to PD amongst US nephrologists
impact selection of dialysis modality. Risk of infectious
complications, specially PD peritonitis and catheter-related
problems contribute to the selection bias. Systemic factors
such as the easy accessibility to HD, ﬁnancial incentives, and
ownership of dialysis units, including units owned by large
dialysis organization (LDOs), as well as physician education
and exposure to PD during training also play an important
role in the selection of RRT for ESRD patients. Strategies to
preventperitonitis,ultraﬁltrationfailure,managingcatheter-
related complications, and improving adequacy of dialysis as
well as education of patients and medical staﬀ may all help
with increasing PD utilization.
2.Why PD beforeHD?
Along with improved survival, other long-term goals of
ESRDpatientsaretoimprovequalityoflife,preserveresidual
renal function, and reduce morbidity. Many young ESRD
patients will likely receive PD, HD, and renal transplantation
at diﬀerent points over their lifetime. Better survival on PD
compared to HD during ﬁrst two years of dialysis treatment
is one of the compelling reasons to start patient on PD
ﬁrst. In the last decade, infection-related complications are
higher and appear to be increasing in HD patients, whereas
such complications are steadily declining in PD patients [1].
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sites, lower cost of therapy, convenience of home therapy, a
ﬂexible schedule, and increased freedom from the patient’s
perspective are other reasons to oﬀer PD as the ﬁrst choice
modality.
3.SurvivalAdvantage
Comparisons of mortality outcomes in HD and PD patients
in studies have yielded conﬂicting results. Vonesh et al.
analyzed the Medicare data of 398,340patients initiating
dialysis between 1995 and 2000. They showed survival
diﬀerences between HD and PD varied substantially accord-
ing to the underlying cause of ESRD, age, and level of
baseline co morbidity. The adjusted mortality rates were
either the same or higher for HD as compared to PD
in most patient groups except in older diabetic patients
[4]. Heaf and colleagues reported survival beneﬁt for PD
during the ﬁrst two years of dialysis treatment from the
Danish Terminal Uremia registry data [5]. Similar survival
beneﬁts were reported from Canadian cohort of dialysis
patients initiating dialysis between 1990–1994 [6]. However,
among CHOICE cohort, Jaar et al. reported no diﬀerence
in the mortality risk during ﬁrst year but signiﬁcantly
higher mortality risk for patients undergoing PD relative
to HD during second year [7]. The CHOICE study has
been criticized for collection of data after dialysis initiation,
recruitment bias and data analysis. Mehrotra et al. examined
the US Renal Data System (USRDS) for secular trends in
survival among patients treated with HD and PD on day 90
of ESRD (HD 620, 020 patients; PD 64 406 patients) in three
3-year cohorts (1996–1998, 1999–2001, and 2002–2004) for
up to 5years of follow up. Authors reported higher risk of
death seen with PD in earlier cohorts which improved with
time and there was no signiﬁcant diﬀerence in the risk of
death for PD and HD patients for the 2002–2004 cohorts
during 5-year followup. Subgroups analysis based on age,
diabetes status, and baseline comorbidity showed greater
improvement in survival among patients treated with PD
relative to HD at all follow-up periods [8]. In a separate
study of 66,381 PDpatients, comparing 1996–1998 cohorts
to 2002–2004 cohorts, the risk of death and switch to HD
were 45% and 38% lower, respectively, in the later cohort
[9]. Researchers compared mortality rates between patients
treated with PD and HD (including home HD) using data
from 27,015patients in the Australia and New Zealand
Dialysisand TransplantRegistry. Overallmortalityrateswere
signiﬁcantly lower during the 90- to 365-d period among
those being treated with PD at day 90 (adjusted hazard
ratio [HR] 0.89; P.001) [10]. Five-year survival on dialysis
has improved signiﬁcantly in last one decade. However,
survival probabilities were improved more for patients on
PD compared to HD. For incident patients on hemodialysis
or peritoneal dialysis, survival probabilities in 1998–2002
were 7.2 and 14.8percent higher, respectively, than in 1993–
1997 [1]. The improvement in survival for diabetics was 12.9
and 21.8 percent for HD and PD, respectively. Similarly for
patients with hypertension, the improvement was 4.0 and
13.2percent for HD and PD, respectively [1]. In contrast to a
c o m m o nb e l i e ft h a ts u r v i v a lo nP Di si n f e r i o ra sc o m p a r e d
to HD, the converse is actually the case for most patient
groups,particularlyintheﬁrst fewyearsofdialysis.Although
the rates of native AVF are lower in PDpatients, it has not
translated into inferior survivals and it would be prudent to
protect the veins of a PD patient specially those who are not
a transplant candidate [11].
4.PreservationofResidualRenalFunction
Residual renal function (RRF) is clinically important as
it contributes to adequacy of dialysis, quality of life, and
mortalityindialysis patients.RateofdeclineinRRFisamore
powerful prognostic factor than baseline RRF associated
with all-cause mortality in PD patients [12]. Loss of RRF
reduces small and middle molecular weight toxin clearance,
decreased erythropoietin synthesis and increase sodium,
phosphorus, and water retention [13]. These can lead to
anemia, malnutrition, congestive heart failure, cardiac hype-
rtrophy, atherosclerosis, vascular, and valvular calciﬁcation;
and overall increase in cardiovascular morbidity and mor-
tality [13] .I nas t u d yM o i s te ta l .s h o w e dt h a tP Dh a d
65% lower risk of loss of RRF compared to HD during ﬁrst
year of RRT in incident ESRD patients [14]. Maintenance of
RRF has shown direct correlation with patient survival. In
a prospective observational study involving 231 chronic PD
patients,Wang andcolleaguesreported 50%reductioninall-
cause mortality and cardiovascular death for every 1ml/min
increase in residual GFR [15]. It is imperative to periodically
measure both the delivered dose of PD and RRF and make
necessary adjustments to the dialysis prescription as RRF
is lost. Eﬀorts to maintain RRF with use of biocompatible
PD solutions and treatment with ACE inhibitors should be
considered [16].
5.LowerInfectionand HospitalizationRates
After cardiovascular disease, infection is the most common
cause of death in dialysis patients accounting for 33deaths
per 1000patient years in the USRDS cohort of 2001–
2003 [1]. In a single-center observational cohort of dialysis
patients (n = 181; HD 119 and PD 62) from 1999 to 2005,
as expected only HD patients had bacteremia (0.16/year)
and PD patients had peritonitis (0.24/year), the investigators
however did not ﬁnd any diﬀerence (P = .24) in the
rates of overall infection between HD and PD patients [17].
According to USRDS data from 2007, the rates of admission
for bacteremia/septicemia were 1.5–2.3 times higher in HD
patients reaching 102 per 1000patient years compared to
66.7 per 1000patient years in PD patients [1]. Comparing
HD to PD as initial RRT modality, HD patients are at twice
as higher risk of hospitalization from septicemia than PD
patients. In another longitudinal cohort of incident dialysis
patients with seven years of followup, the adjusted risk of
death from septicemia was almost double in HD patients
compared to PD patients (9.79 versus 4.81, P<. 01) [18].
Since the introduction of twin bags and Y set system and use
of “ﬂush before ﬁll” technique, the rates of PD peritonitis
have gone down signiﬁcantly over the last few years. Use
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occurrence of both S Aureus and gram negative infections,
including pseudomonas, and should be applied as a best
practice [19].
6.Qualityof LifeandPatientSatisfaction
PD oﬀers home-based therapy, thus there is no need to go
to dialysis unit three times per week and no time spending
in dialysis unit. Most PD patients pay visit to see their
physician once a month. PD oﬀers a ﬂexible schedule with
opportunities to travel and participate in other activities.
Patient satisfaction is better amongst PD patients as com-
pared those on HD [20]. In CHOICE cohort researchers
surveyed 736new dialysis patients from 37 centers regarding
their satisfaction with treatment. Patients receiving PD
were much more likely than those receiving HD to give
excellent ratings of dialysis care overall and signiﬁcantly
more likely to give excellent ratings for each speciﬁc aspect
of care rated. The diﬀerences between peritoneal dialysis
and hemodialysis patient satisfaction persisted even after
adjustment for patient age, race, education, health status,
marital status, employment status, distance from the center,
and time since starting dialysis [21].
7.BetterGraft SurvivalinTransplant Patient
It would be preferable to start ESRD patients waiting for
renal transplant on PD; especially ones with live donors. In
a case-control study the incidence of delayed graft function
was less, and the drop in serum creatinine was faster in
continuous ambulatory peritoneal dialysis (CAPD) patients
compared to HD patients. No diﬀerences in surgical com-
plications or infections were observed between CAPD and
HD patients [22]. One study reported high graft thrombosis
with PD and high acute rejection episodes in HD patients
but overall graft survival was similar [23]. While another
study reported that the choice of pretransplant dialysis
modality did not inﬂuence waiting time for transplant or
the results of transplantation [24]. A study from the United
States suggested that the use of PD immediately before
transplantation predicts a 3% lower risk for graft failure
(P<. 05) and 6% lower risk for recipient death (P<. 001).
Better recipient and graft survival was noted when patient
received at least 50% of their pretransplant RRT time as PD
[25].
8.EconomicIssues
Per Center for Medicare and Medicaid, the cost diﬀerence
between HD and PD was $13,900 in 2001. Though the costs
of both modalities have increased over years, the diﬀerence
in cost has also increased to $20,000 in 2009 [1]. Per person,
per year cost for HD was $73,008 versus $53,446 for PD
[1]. Until recently in the US, there was a ﬁxed “composite
rate” for dialysis-related services and in addition providers
were also reimbursed for “injectable” medications (such
as erythrocyte stimulating agents, intravenous iron, and
vitamin D analogues) on an “as used” basis. On an average,
PD patient uses less intravenous medications than in-center
HD patient which contributes to higher cost of HD.
Shihetal.evaluatedtheimpactofinitialdialysismodality
choice and subsequent modality switches on Medicare
expenditure in a 3-year period involving 3423patients with
new initiation of dialysis. After adjusting for patient charac-
teristics, the annual Medicare expenditure was signiﬁcantly
lower for patients with peritoneal dialysis as the initial
modality (56,807dollars versus 68,253dollars) (P<. 001).
“Peritoneal dialysis, with at least one switch” and “hemodial-
ysis, with at least one switch” had a lower or similar annual
expenditure of $66,639 and $72,335, respectively [26]. In a
recent cost comparison study of 463 dialysis patient with
12% of PD patients, the rate of hospitalization was less in
PD patients compared to HD patients in the year following
initiation of dialysis and had signiﬁcantly lower health care
cost over 12month period. ($173,507 versus $129,997, P =
.03) [27].
9.Achieving SoluteClearance
As with HD, the clearance of small solutes has been thought
to be an important predictor of survival in PD patients. The
Canada-USA (CANUSA) study examined the relationship
between dialysis adequacy and mortality, hospitalization,
and technique failure in PD patients. According to this study
results, a decrease of 5L/1.75m2 in creatinine clearance per
week was associated with a 7% increase in relative risk of
death. Also, a decrease of 0.1units Kt/V per week was asso-
ciated with a 5% increase in the relative risk of death. Based
on these results, NKF-DOQI guidelines suggested a weekly
Kt/V of 2.0 and weekly creatinine clearance of 60L/1.73m2
for PD patients. These Kt/V and creatinine clearance were
diﬃcult to achieve in large and anuric patients. However, the
CANUSAstudyassumed thatrenal and peritonealclearances
were similar and additive [28]. The ADEMEX study showed
that increasing peritoneal small solute clearance achievable
in clinical practice did not improve survival in PD patients
[29]. In a study from Hong Kong, Lo et al. showed that there
was no diﬀerence in outcome for patients with Kt/Vurea
maintained above 2.0 versus Kt/Vurea between 1.7 and 2.0
[30]. Reanalysis of CANUSA data showed no association
between peritoneal clearance an dt h er e l a t i v er i s ko fd e a t h .
Based on these results, the 2006 NKF-DOQI guidelines
suggested a minimum weekly Kt/Vurea target of 1.7 for PD.
These lower adequacy targets are easier to achieve in practice
and have not translated in inferior outcomes.
10.AdequateUltraﬁltrationand
Volume Control
Inability to achieve adequate ultraﬁltration and failure to
maintain volume homeostasis is another cause of technique
failure in PD patients. Prevalence of ultraﬁltration failure
is reported to be between 1.7% and 13.7% [31]. Failure
to follow ﬂuid and dietary sodium restrictions necessi-
tates use of more hypertonic solution to achieve adequate
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to hyperglycemia, weight gain, and hyperlipidemia. Fur-
thermore, chronic exposure to hypertonic solutions which
degrade into AGEs may alter peritoneal membrane trans-
port characteristics, converting a low transporter into high
transporter [32]. In two diﬀerent PD cohorts—one from
Netherlands and one from Japan—failure of ultraﬁltration
was the biggest reason for withdrawal from CAPD [33, 34].
However, in these both cohorts the major modality was
CAPD and Icodextrin was not used. Icodextrin is a glucose
polymer that may be used as an osmotic alternative to
dextrose in PD solutions. In a Japanese cohort of greater
than 7000patients, Kuriyama et al, showed that the dropout
rateinpatientswho usedIcodextrin(8.9%),wassigniﬁcantly
lower than those using dextrose (14.5%), (P<. 0001)
[35]. Newer biocompatible solutions without dextrose, and
having a more physiologic pH have been associated with
better preservation of peritoneal membrane; however, most
human studies done with biocompatible solutions had
short followup duration and clear evidence of beneﬁt is
lacking [36, 37]. Mechanical complications like catheter
malposition or malfunction are also known to cause failure
of ultraﬁltration. Many causes of catheter malfunction such
as occlusion by bladder or bowels can be corrected with
use of laxatives or emptying the bladder. Obstruction due
to clots can be dislodged with injecting heparinized saline;
and if unsuccessful, by instillation of TPA or urokinase
in the catheter. Common mechanical problems of omental
trapping, adhesion formation, and so forth can be corrected
through laparoscopic means by performing omentopexy,
adhesiolysis, resection of epiploic appendices, colopexy, and
so forth [38].
11.EducationIsImportant
Adequate understanding and education of patient and
nephrologists are key to improve utilization rates of PD. In
dialysis centers with limited knowledge and experience in
performing PD, the recommendation “PD ﬁrst” can lead
to poor outcomes. Along with the education of physicians
and medical staﬀ, patients with chronic kidney disease
approaching ESRD should be educated about kidney failure
and renal replacement therapies. The National Pre-ESRD
Education Initiative involved 15,000patients from 932 refer-
ringnephrologistsbetween1997and2001.Uponcompletion
of the program 55% chose hemodialysis, while 45% chose
peritoneal dialysis, suggesting important inﬂuence of pre-
dialysiseducationonselectionofmodality oftreatment [39].
Low prevalence of PD leads to inadequate exposure
of in-training fellows to this modality. This in turn leads
to vicious cycle in which uncomfortable nephrologists not
oﬀering PD to their patient and further reducing its use. To
oﬀset these concerns, the training programs must provide
fellows adequate exposure to PD. Programs with limited
access should oﬀer fellows elective rotation in centers with
larger PD population and have a core curriculum for PD
including text and visual aids.
In conclusion, there is suﬃcient evidence to support the
initiative of PD ﬁrst and with improving PD techniques,
greateruse ofbiocompatiblesolutions,improvedpatientand
physician education, and the bundling of dialysis services,
providers will be more receptive towards the PD ﬁrst
initiative.
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